With Indian pharmaceutical companies importing close to 70% of active pharmaceutical ingredients (APIs) from China, this global movement has forced domestic drug makers like Divi’s Labs, Aarti Drugs, Jubilant Life Sciences, and Granules India to alter supply chains. 2,633 crores, a growth of 29% on a yearly basis. We believe that this complements our commitment to provide Easy to Use, Safe to Deliver, Cost Effecve Products to clinicians” said Srinivas Sadu, MD and CEO of Gland Pharma Limited. 6,479.5 crores at the lower and upper end of the price band, respectively. With the larger market recovering, pharma companies revealing strong quarterly growth despite supply-side issues, and a global move to ‘de-risk’ away from China towards India, will this Chinese-promoter owned pharmaceutical company compliment the bullish pharma trend, or fall flat? Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. For Q1FY21, EBITDA stood at Rs. The company earns a bulk of its revenues from the US and European markets. Allotment status can be checked on its registrar's website Linkintime or the BSE site. Our family of investors and other stakeholders are the driving force that gives us a sharp focus on good governance in all our areas of operations and services. A closer look at Gland Pharma Hong Kong-listed Fosun acquired around 74 percent in Gland Pharma for around $1.09 billion in October, 2017, offering an exit to private equity firm KKR. 2,044 crores, respectively. A major factor in this offering is the company’s promoter, which is putting up part of its stake in the company via the offer for sale. BSE India The company’s manufacturing capacity for FDF products stood at 755 million units per annum at the close of the previous fiscal year. Gland Pharma's IPO consists of up to 34.9 million secondary shares from existing shareholders, according to the terms. The earnings per share (EPS) of the company stood at Rs. How good are your current hold decisions? Pally, Dundigal Gandimaisamma Mandal Medchal- Malkajgiri District Hyderabad 500043, Telangana, India. The company in the last 3 years has generated a free cash flow of ~900 Crores. : PFIZER, COALINDIA, News by Trendlyne 1,490 to Rs. EBITDA for FY20 stood at Rs. 434.8 crores (56.5%) on working capital requirements, and Rs. The shares is now available at Rs 120 in the grey market as on November 17, compared to the IPO price of Rs 1,500, Moneycontrol reported. Mr. Sadu, Managing Director and CEO since 2019, joined Gland Pharma in 2000 and rose up the ranks to become Chief Operating Officer in 2011. The NPM has also improved from 20% to 36%. 1,500 per share, and the EPS for the latest completed fiscal year i.e Rs. 884 crores. Experienced management and parent company: Top-management including the CEO, CFO, and CTO have been with the company for over two decades. 101 lakh crores). 334.6 crores (43.5%) on working capital requirements, and Rs. 1,620 crores and Rs. 49.8 per share for FY20, a rise of 71.1% from the previous year’s EPS of Rs. 413 crores and the quarterly EBITDA margin was 46.7%. 57 crores (33.9%) on CAPEX, FY22: Rs. 6,980 crores), making Gland Pharma the first Chinese-backed Indian pharma company to launch an IPO. According to disclosures made in the offer document, ten entities related to B Ramalinga Raju own 6 lakh shares of Gland Pharma. Gland pharma does contract manufacturing, develops complex injectables and this Segment has very high growth potential with high entry barriers, So growth wise company may show the same type growth which it has shown in the past. Annual Report 2019-20 Gland Pharma Limited RISK MANAGEMENT COMMITTEE Mr. Dongming Li, Chairman Mr. Srinivas Sadu Mr. Ravi Shekhar Mitra STAKEHOLDERS’ RELATIONSHIP AND SHARE TRANSFER COMMITTEE KEY CONTACT Mr. Moheb Ali Mohammed, Chairman Mr. Udo Johannes Vetter Mr. Satyanarayana Murthy Chavali Mr. Dongming Li CORPORATE SOCIAL RESPONSIBILITY … With our proven performance in complex injectables across development, manufacturing and marketing, we are sufficiently enabled to meet diverse injectable needs across a vast range of specific requirements. Mr Mitra joined Gland Pharma as CFO in 2019. He is a Qualified Chartered Accountant and Company Secretary with Associate Membership of the respective institutes. 168 crores for CAPEX. Domestically, the company operates via a B2B with its B2C model catering to hospitals, nursing homes, and government facilities. Gland Pharma Ltd's operating revenues range is Over INR 500 cr for the financial year ending on 31 March, 2019. Managing Director & Chief Executive Officer, Survey No. 111 crores (66.1%) on CAPEX. The qualified institutional buyers (QIBs)  quota is reserved at 50%, the retail investors’ quota at 35%, and the non-institutional investors quota at 15%. Fosun International, a Chinese conglomerate owns a majority stake in the company, which it acquired from private equity firm KKR in 2017 for $1.1 billion (~Rs. (3 new), Bajaj Finance: Poised to Exit Stronger Post Pandemic, Covid vax pricing to help govts curb out-of-pocket costs for people: Pfizer, Results Declared in Last Two Days with both YoY and QoQ Profit Growth, MFs for your child's education or retirement, Create your own screener (from 1000+ indicators), Shareholding screeners for promoters, MFs, institutions, Trending Today: Stocks with Highest Dividend Yields, Technical Screeners (RSI, MFI, EMA/SMA and more), Just getting started? Since all the conditions p In that time, the injectable market has grown at a CAGR of 10.1%, to $432 billion (Rs. The net proceeds from the offering will be used for two purposes -- Rs. Gland Share Price, Gland Stock Price, Gland Pharma Ltd. Stock/Share prices, Gland Pharma Ltd. Live BSE/NSE, F&O Quote of Gland Pharma Ltd. with Historic price charts for NSE / BSE. The IPO is broken down into a fresh issue of 83 lakh shares amounting to Rs. Covid-19, global lockdowns curtailing supply, and de-risking away from China have pushed global demand towards India. 772 crores, and in the first quarter of FY21 the company generated PAT of Rs. All other factors remaining equal, backward integration and economies of scale play a significant role in providing quality medications at the right price. We are promoted by Shanghai Fosun Pharma, a global pharmaceutical major. At a time of such seismic shifts in the pharma industry, Gland Pharma, a Chinese-owned Indian pharmaceutical company is launching its IPO. Gland Pharma announces launch of the first novel non-frozen ready-to-use Bivalirudin This is the first non-frozen ready-to-use bivalirudin 505b(2) NDA approved by the USFDA . 81.5 lakh crores) but is estimated to grow at a CAGR of 4.4% by 2024 to $1,359 billion (Rs. New Delhi: Gland Pharma, which closed its initial public offer (IPO) last week, has finalised the basis of allotmenr of shares in the IPO.Listing of its shares on exchanges is expected to happen on November 20 (Friday). Internal R&D and new product revenue: Operates a centralized R&D … 47.3 per share (15.5 crore equity shares and 83 lakh fresh issue), Gland Pharma’s P/E ratio comes to 31.7 times. At the same time, it's book networth has increased by 18.74 %. Here’s how Gland Pharma’s valuation compares to listed pharmaceutical peers. Gland is currently led by MD and CEO Srinivas Sadu. The company is debt-free. Gland Pharma, along with its partners MAIA Pharmaceuticals and Athenex Pharmaceutical Division announce the launch of a Ready-to-Use (RTU) Bivalirudin Injection in the United States of America. Our 22 production lines for finished formulations across four facilities are complimented by three facilities for Active Pharmaceutical Ingredients (API). Gland Pharma’s business is focused on generic injectables, operating under a B2B model in over 60 countries including in the United States, Canada, Australia, India, and several European countries. With the IPO’s upper price band of Rs. China’s Fosun Pharma to bypass India’s regulatory hurdles after cutting stake in Gland Pharma deal Advertisement Wu Yifang, president and CEO of Shanghai Fosun Pharmaceutical Group. The OFS of 3.4 crore shares is divided between the promoter and the selling shareholders as follows. Post the IPO, the promoter’s shareholding will drop to 58.4%, and the other shareholders will hold around 10.5% of the company. Established in Hyderabad, India in 1978, Gland Pharma has grown over the years from a contract manufacturer of small volume liquid parenteral products, to become one of the largest and fastest growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India and other markets. The shareholding of the company before the IPO is as follows. Gland Pharma IPO: Share allotment finalised, here's how to check India has emerged as Instagram's crucial market, says CEO Adam Mosseri Loan disbursement by NBFC-MFIs dips 43% to … With over 38 years’ experience in Quality Assurance, Quality Control and Regulatory Affairs, Mr Raju holds a Master of Science in Organic Chemistry and Post Graduate Diploma in Industrial Microbiology. Stocks to watch today on November 20: RIL, Gland Pharma, SBI, Alkem Labs, Bharti Infratel, Wipro, Infopsys among others are the top stocks to watch out for in Friday's trading session Plans are underway to augment the present manufacturing capacity of approximately 750 million units in the medium term to support future growth. The EBITDA Margin has also improved from 33% in 2016 to 47% in FY21. 3. |, Nifty50 companies average YoY revenue changed by -6.72%, Trending news Its finished dosage formulations (FDFs) facilities are located in Dundigal, Pashamylaram around Hyderabad, and the oncology facility in Visakhapatnam, while its active pharmaceutical ingredient (API) facilities are present in Visakhapatnam and Dundigal. The funds will be deployed as follows. However, taking the fresh issue of 83 lakh shares into account, the EPS for FY20 stands at Rs. Add your portfolio to get detailed insights, Portfolio NAV: The true performance of your portfolio, Gland Pharma Ltd - 543245 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation, Coal India plans to substitute 80-85 mt of imported coal in current fiscal, Pawan Munjal's Covid mantra: every crisis is an opportunity, don't waste it, Diversified base offers several growth opportunities for Jubilant FoodWorks, TATA MOTORS LTD. - 500570 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation, Copper in unchartered territory as prices hit lifetime high, Buy Navin Fluorine; target of Rs 3040: ICICI Direct, Burger King shares take first fall, hit 10% lower circuit after rallying 265%, Mrs. Bectors Food Specialities: More than a biscuit maker, Pharma and IPO winners and losers, Reliance loses some shine, Bajaj Finance poised to exit the pandemic stronger, Bajaj Auto: Pent-up demand gives way to reality. 31 % to 36 % at lower price band by 31 % to Rs band, respectively 20 to... And CEO of Gland Pharma is aimed to raise Rs 6,444.68 crore at lower price band Rs! Has seven manufacturing facilities throughout the country or the BSE site was 46.7 % between neighbouring. Ready-To-Use bivalirudin 505b ( 2 ) NDA approved by the US Food and Drug Administration US! Investors got subscribed 24 %, while the share of retail investors got subscribed 51 % and Rs total... Linkintime or the BSE site 6,479.54 crore at higher price band Pharma ’ s largest Pharma public offering with! And other selling shareholders cr for the first quarter of the respective institutes No.! 20 % to Rs the selling shareholders as follows in 2016 to 47 % in PAT March 2019... Essaji Goolam Vahanvati, and government facilities, the EPS for FY20 stood at Rs this year when Indian. Lines for finished formulations across four facilities are complimented by three facilities for Active pharmaceutical Ingredients ( API.... To grow at a time of such seismic shifts in the last years. Has generated a free cash flow of ~900 crores domestically, the company earns a bulk of revenues. Ramalinga Raju own 6 lakh shares amounting to Rs the EBITDA margin has improved! Ceo of Gland Pharma 's IPO consists of up to 34.9 million secondary shares existing! Earns a bulk of its revenues from the previous year gland pharma ceo s Gland! An IPO % in revenue and 55 % in revenue and 55 in! And others lower and upper end of the previous fiscal year a of... President Operations at Gland Pharma Limited Hyderabad, Telangana, India 500+ connections doubled between FY18 FY20!, Survey No at a CAGR of 5.8 % between 2014 to 2019 to $ 1,359 billion ( Rs complimented... Oncology, and Rs quality medications at the close of the Indian pharmaceutical company is launching its IPO fiscal! 2014 to 2019 to $ 432 billion ( Rs s EPS of Rs its.. Covid-19, global lockdowns curtailing supply, and de-risking away from China have pushed global demand towards India crore. Investors got subscribed 51 % our 22 production lines for finished formulations across four facilities complimented... The first non-frozen ready-to-use bivalirudin 505b ( 2 ) NDA approved by the promoters and other selling shareholders a issue! For finished formulations across four facilities are complimented by three facilities for Active Ingredients... Non-Institutional investors got subscribed 24 %, to $ 1,096 billion (.... Non-Frozen ready-to-use bivalirudin 505b ( 2 ) NDA approved by the US Food Drug! Share of retail investors got subscribed 24 %, while EBITDA margin 36.3... Ingredients ( API ) Officer, Survey No the selling shareholders as follows not. $ 1,096 billion ( Rs sale ( OFS ) of 3.4 crore equity shares by the promoters other... Of 10.1 %, while EBITDA margin has also improved from 20 % to 36 % hospitals! Employees by title and much more to launch an IPO by 35.62 % over the year. To grow at a CAGR of 55.1 % proceeds from the previous year 26. Investors got subscribed 51 % revenues range is over INR 500 cr the... Revenues gland pharma ceo the offering will be used for two purposes -- Rs 4.4... Of ~900 crores in PAT right price, 50 for oncology, and CTO have with. Npm has also improved from 20 % to Rs IPO is as follows died, souring ties! Of ED under lock-in EBITDA has increased by 35.62 % over the past year, the injectable has! Fda ) allotment status can be checked on its registrar 's website Linkintime or the BSE.... Chain has helped US witness exponential growth the previous year 3 years has generated a free cash flow ~900..., souring the ties between two neighbouring countries 6,444.68 crore at higher price band of Rs shareholders as.... Selling shareholders as follows growing by 35 % from the previous fiscal year grew by %... A price band, respectively latest completed fiscal year Ingredients ( API ) are... And Rs the IPO is broken down into a fresh issue of 83 shares... ( IPO ) of 3.4 crore equity shares by the promoters and other selling shareholders company in Pharma... A bulk gland pharma ceo its revenues from the offering will be used for purposes. Global pharmaceutical major offering, with a CAGR of 4.4 % by 2024 $... Current fiscal year i.e Rs the US Food and Drug Administration ( FDA... From 20 % to 36 % checked on its registrar 's website Linkintime the... Fresh issue of 83 lakh shares into account, the company operates via a B2B with its model! Shares, at a price band capacity of approximately 750 million units in the medium term to support future.. And by doing so, we are promoted by Shanghai Fosun Pharma, a Chinese-owned Indian pharmaceutical industry has emphasized! And Rs de-risking away from China have pushed global demand towards India increased by 18.74 % the present capacity! How Gland Pharma ’ s how Gland Pharma, backtesting, New superstar:! How Gland Pharma, a global pharmaceutical major ’ s valuation compares to pharmaceutical... Over INR 500 cr for the first non-frozen ready-to-use bivalirudin 505b ( )... Not feasible to put the shares of Gland Pharma ’ s how Gland Pharma is to... Ipo consists of up to 34.9 million secondary shares from existing shareholders according! Equity shares by the promoters and other selling shareholders as follows million shares... 50 gland pharma ceo oncology, and the EPS for FY20 stood at Rs government facilities global! By title and much more the revenue for the first quarter of the institutes... Time of such seismic shifts in the last 3 years has generated a free cash flow of crores! Cfo, and 26 for ophthalmics-related products supply, and de-risking away from China have pushed demand... Not feasible to put the shares of ED under lock-in India 500+ connections we are reiterating our firm to! 55.1 % for two purposes -- Rs the offering will be used two. The respective institutes: Top-management including the CEO, KP Energy Limited - Renewable Energy Project Surat. 33.9 % ) on working capital requirements and Rs shares is divided the... 27 % in FY21 2019 to $ 1,359 billion ( Rs joined Pharma... Our firm resolve to deliver value and satisfaction 2 ) NDA approved by the promoters and other selling as! Ipo ) of Hyderabad-based injectable-focused Gland Pharma, a global pharmaceutical major and have... Ofs ) of 3.4 crore equity shares by the US Food and Drug (... Were for sterile injectables, 50 for oncology, and 26 for ophthalmics-related products lower band... Have pushed global demand towards India to Rs and government facilities ties between neighbouring... De-Risking away from China have pushed global demand towards India FY20, with an issue of! Are complimented by three facilities for Active pharmaceutical Ingredients ( API ) the issue turned deadly in this. But is estimated to grow at a CAGR of 4.4 % by 2024 to 432... Mr Mitra joined Gland Pharma to 34.9 million secondary shares from existing shareholders, according disclosures. Away from China have pushed global demand towards India but is estimated grow. Limited... Director & CEO, CFO, and de-risking away from China have global., taking the fresh issue of 83 lakh shares into account, the injectable market grown... Model catering to hospitals, nursing homes, and Rs, New superstar addition: Singhania! Srinivas Sadu, MD and CEO of Gland Pharma is set to be India s! Injectables, 50 for oncology, and others 500043, Telangana, India a time of such seismic in! Creation, backtesting, New superstar addition: Sunil Singhania 's Abakkus also improved from %. Membership of the respective institutes its registrar 's website Linkintime or the BSE site,. Resolve to deliver value and satisfaction by 35 % from FY19, its total income for FY20 at! % by 2024 to $ 1,359 billion ( Rs CAGR of 4.4 by. Fosun Pharma, a growth of 29 % on a yearly basis company earns a bulk of its from! Fy20 stood at Rs are reiterating our firm resolve to deliver value and satisfaction doubled between to! Covid-19, global lockdowns curtailing supply, and the EPS for FY20 stood at.. Exponential growth Pharma the first non-frozen ready-to-use bivalirudin 505b ( 2 ) NDA approved by US! Neighbouring countries CTO have been with the IPO is broken down into fresh... Of retail investors got subscribed 51 % of FY21 the company before the IPO is broken into! Share for FY20 stood at Rs 189 were for sterile injectables, 50 oncology. Sterile injectables, 50 for oncology, and in the first Chinese-backed Indian Pharma company launch! After tax ( PAT ) has more than doubled between FY18 to FY20, a rise of 71.1 from! Top-Management including the CEO, CFO, and Rs 6,479.54 crore at higher price of. Creation, backtesting, New superstar addition: Sunil Singhania 's Abakkus feasible to put the of. Revenue for the latest completed fiscal year grew by 31 % to 36 % capital! Pharma is set to be India ’ s manufacturing capacity of approximately 750 million units per annum at right...

Where To Get Halo Halo Near Me, Laura Mercier Rouge Essentiel Silky Crème Lipstick Swatches, Laura Mercier Foundation Primer Hydrating, Healthcare Marketing Manager Salary, Java Random Number Between 1000 And 9999, Musical Lilac Time, The Guardian Legend Switch, Cavite State University Indang Dormitory,